These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26044977)

  • 21. The tachykinergic system as avenues for drug intervention.
    Rameshwar P
    Recent Pat CNS Drug Discov; 2012 Aug; 7(2):173-80. PubMed ID: 22472024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioactive analogs of neurotensin: focus on CNS effects.
    Boules M; Fredrickson P; Richelson E
    Peptides; 2006 Oct; 27(10):2523-33. PubMed ID: 16882457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotensin agonists: possible drugs for treatment of psychostimulant abuse.
    Richelson E; Boules M; Fredrickson P
    Life Sci; 2003 Jun; 73(6):679-90. PubMed ID: 12801589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.
    Sharma RP; Janicak PG; Bissette G; Nemeroff CB
    Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tachykinins: role in human gastrointestinal tract physiology and pathology.
    Improta G; Broccardo M
    Curr Drug Targets; 2006 Aug; 7(8):1021-9. PubMed ID: 16918330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions.
    Rostene W; Azzi M; Boudin H; Lepee I; Souaze F; Mendez-Ubach M; Betancur C; Gully D
    Ann N Y Acad Sci; 1997 Apr; 814():125-41. PubMed ID: 9160965
    [No Abstract]   [Full Text] [Related]  

  • 27. Neurotensin: role in psychiatric and neurological diseases.
    Cáceda R; Kinkead B; Nemeroff CB
    Peptides; 2006 Oct; 27(10):2385-404. PubMed ID: 16891042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of neuropeptide systems in schizophrenia: human studies.
    Cáceda R; Kinkead B; Nemeroff CB
    Int Rev Neurobiol; 2007; 78():327-76. PubMed ID: 17349866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists.
    Joos GF; De Swert KO; Pauwels RA
    Eur J Pharmacol; 2001 Oct; 429(1-3):239-50. PubMed ID: 11698044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of tachykinin receptors in the uterus of the oestrogen-primed rat.
    Magraner J; Pinto FM; Anselmi E; Hernandez M; Perez-Afonso R; Martín JD; Advenier C; Candenas ML
    Br J Pharmacol; 1998 Jan; 123(2):259-68. PubMed ID: 9489614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurotensin: an endogenous antipsychotic?
    Kinkead B; Nemeroff CB
    Curr Opin Pharmacol; 2002 Feb; 2(1):99-103. PubMed ID: 11786316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs.
    Stowe ZN; Bissette G; Nemeroff CB
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):49-59. PubMed ID: 1679273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?
    Cáceda R; Kinkead B; Nemeroff CB
    Semin Clin Neuropsychiatry; 2003 Apr; 8(2):94-108. PubMed ID: 12728409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurotensin agonists as an alternative to antipsychotics.
    Boules M; Fredrickson P; Richelson E
    Expert Opin Investig Drugs; 2005 Apr; 14(4):359-69. PubMed ID: 15882113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress.
    Dawson LA; Porter RA
    Future Med Chem; 2013 Sep; 5(13):1525-46. PubMed ID: 24024945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous tachykinins facilitate transmission through parasympathetic ganglia in guinea-pig trachea.
    Watson N; Maclagan J; Barnes PJ
    Br J Pharmacol; 1993 Jul; 109(3):751-9. PubMed ID: 7689402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tachykinin regulation of basal synovial blood flow.
    Ferrell WR; Lockhart JC; Karimian SM
    Br J Pharmacol; 1997 May; 121(1):29-34. PubMed ID: 9146883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia.
    Nikiforuk A
    Curr Pharm Des; 2016; 22(14):2093-116. PubMed ID: 26818861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.
    Patacchini R; Barthó L; Maggi CA
    Br J Pharmacol; 1997 Dec; 122(8):1633-8. PubMed ID: 9422808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases.
    Lecci A; Maggi CA
    Expert Opin Ther Targets; 2003 Jun; 7(3):343-62. PubMed ID: 12783571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.